Surgical Science Sweden ABSUSRF -2.20%82 EBITDA Margin % is 9.71% as of Mar. 2026, which is 63% below its 10-year median of 26.34. GuruFocus rates SUSRF with a GF Score™ of 82/100 and a GF Value™ of $14.30 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks worse than 59.88% on this metric.
Surgical Science Sweden AB (OTCPK:SUSRF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Surgical Science Sweden AB EBITDA Margin % Related Terms
Surgical Science Sweden AB EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SUSRF vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, Surgical Science Sweden AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB (SUSRF) has a EBITDA Margin % of 9.71% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Surgical Science Sweden AB and its competitors. This is 63% below median its historical median of 26.34. Over the past decade, Surgical Science Sweden AB's EBITDA Margin % has ranged from 6.95 to 36.76. According to the industry distribution chart, Surgical Science Sweden AB ranks #400 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 59.9%.
Is Surgical Science Sweden AB's EBITDA Margin % too high?
Surgical Science Sweden AB's current EBITDA Margin % of 9.71% is 63% below median its 10-year median of 26.34. Over the past 10 years, this metric has ranged from a low of 6.95 to a high of 36.76. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Surgical Science Sweden AB's value of 9.71% is 4.9% below this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #400 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Surgical Science Sweden AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #400 out of 668 companies for EBITDA Margin %. This places Surgical Science Sweden AB in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Surgical Science Sweden AB's value of 9.71% is 4.9% below this benchmark. Historically, Surgical Science Sweden AB's own EBITDA Margin % has ranged from 6.95 to 36.76 over the past decade. While the company's 10-year median is 26.34 vs. the industry median of 10.21, Surgical Science Sweden AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current EBITDA Margin % of 9.71% is 4.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current EBITDA Margin % is 9.71%, which is 63% below median its own 10-year median of 26.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.30, compared to a current price of $4.00 — trading 72% below its estimated fair value. The current EBITDA Margin % is 9.71%, which is 63% below median its 10-year median of 26.34 and 4.9% below the Healthcare Providers & Services industry median of 10.21. Surgical Science Sweden AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current EBITDA Margin % is 9.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $4.00 is trading 72% below its estimated GF Value™ of $14.30.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
EBITDA Margin %: 9.71% (63% below median its 10-year median of 26.34)
GF Value™: $14.30 vs. price of $4.00 (72% below fair value)
Industry Position: 4.9% below the Healthcare Providers & Services median (#400 of 668)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
82GF Score
Get the complete analysis for SUSRF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
